OGFOD3 Inhibitors
OGFOD3 inhibitors largely operate by targeting the intricate molecular interactions tied to hydroxylation reactions, particularly the ones associated with 2-oxoglutarate-dependent dioxygenases. Given that OGFOD3 is part of the broader prolyl hydroxylase domain family, it's essential to understand the shared inhibitory mechanisms that can be applied. Compounds such as DMOG, FG-4592, and IOX2 are direct inhibitors of the PHD family. They effectively suppress the hydroxylation reaction either by competing with substrate binding or mimicking the enzymatic substrate. For instance, DMOG, as a 2-oxoglutarate analog, competes for the enzyme's active site, subsequently curbing its activity.
Several compounds, including Cobalt chloride, Desferrioxamine, and L-Mimosine, delve into the iron-dependency of OGFOD3. By either chelating iron or mimicking hypoxic conditions, they effectively alter the environment that these enzymes operate under, thus inhibiting their action. For example, Desferrioxamine's role as an iron chelator means it can starve OGFOD3 of its requisite iron, crucial for its catalytic activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dimethyloxaloylglycine (DMOG) | 89464-63-1 | sc-200755 sc-200755A sc-200755B sc-200755C | 10 mg 50 mg 100 mg 500 mg | $84.00 $301.00 $374.00 $779.00 | 25 | |
A 2-oxoglutarate analog that inhibits several 2-oxoglutarate-dependent dioxygenases, potentially including OGFOD3. | ||||||
N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine-d3 | 808118-40-3 unlabeled | sc-488006 | 10 mg | $12000.00 | ||
Prolyl hydroxylase inhibitor; can affect the activity of OGFOD3 by potentially competing with its substrate binding. | ||||||
IOX2 | 931398-72-0 | sc-482692 sc-482692A sc-482692B | 5 mg 25 mg 100 mg | $131.00 $566.00 $1613.00 | ||
Another PHD inhibitor; suppresses the hydroxylation reaction, likely affecting OGFOD3 activity. | ||||||
Cobalt(II) chloride | 7646-79-9 | sc-252623 sc-252623A | 5 g 100 g | $64.00 $176.00 | 7 | |
Mimics hypoxia conditions by inhibiting prolyl hydroxylases, potentially including OGFOD3. | ||||||
Deferoxamine | 70-51-9 | sc-507390 | 5 mg | $255.00 | ||
Iron chelator that can inhibit iron-dependent enzymes like OGFOD3 by depriving them of iron. | ||||||
BAY 85-3934 | 1154028-82-6 | sc-507384 | 5 mg | $205.00 | ||
PHD inhibitor; impacts hypoxia-inducible factors, potentially influencing OGFOD3 activity. | ||||||
L-Mimosine | 500-44-7 | sc-201536A sc-201536B sc-201536 sc-201536C | 25 mg 100 mg 500 mg 1 g | $36.00 $88.00 $220.00 $436.00 | 8 | |
Iron-chelating agent; inhibits several 2-oxoglutarate-dependent dioxygenases, potentially impacting OGFOD3. | ||||||
Methyl 3,4-dihydroxybenzoate | 2150-43-8 | sc-269487 | 5 g | $81.00 | ||
Iron chelator that can impact the activity of iron-dependent enzymes like OGFOD3. | ||||||
Etidronate Disodium | 7414-83-7 | sc-205687 sc-205687A | 1 g 5 g | $130.00 $500.00 | ||
Another compound known to affect iron metabolism, potentially influencing OGFOD3's function. | ||||||